Do Antidepressants Influence the Disease Course in Inflammatory Bowel Disease? A Retrospective Case-Matched Observational Study
The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Depression, like adverse events and psychological stress, can trigger relapse in inflammatory bowel disease (IBD); however, the effects of psychoactive drugs on disease course are unclear. METHODS: Using retrospective electronic case note review, after exclusion of five patients on low-dose tricyclic antidepressants we compared the course of IBD in 29 patients (14 ulcerative colitis and 15 Crohn's disease), during the years before (year 1) and after (year 2) they were started on an antidepressant for a concomitant mood disorder to that of controls matched for age, sex, disease type, medication at baseline, and relapse rate in year 1. RESULTS: Patients had fewer relapses and courses of steroids in the year after starting an antidepressant than in the year before (1 [0-4] (median [range]) vs. 0 [0-4], P = 0.002; 1 [0-3] vs. 0 [0-4], P < 0.001, respectively); the controls showed no changes between years 1 and 2 in relapses (1 [0-4] vs. 1 [0-3], respectively) or courses of steroids (1 [0-2] vs. 0 [0-3]). Although there were no differences in the use of other relapse-related medications, outpatient attendances, or hospital admissions, the number of endoscopies fell significantly in the antidepressant group in year 2 compared with year 1 (P < 0.01). No such changes were seen in the controls. CONCLUSIONS: Antidepressants, when used to treat concomitant mood disorders in IBD, seem to reduce relapse rates, use of steroids, and endoscopies in the year after their introduction. These results suggest the need for a prospective controlled trial to evaluate their effects on disease course in patients with IBD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Vandenbroucke, J. P., von Elm, E., Altman, D. G., Gøtzsche, P. C., Mulrow, C. D., Pocock, S. J., Poole, C., Schlesselman, J. J., Egger, M., & Initiative, F. T. S. (2007) · PLoS Medicine · doi:10.1371/journal.pmed.0040297 · Cited by 8,613
Trivedi, M. H., Rush, A. J., Wisniewski, S. R., Nierenberg, A. A., Warden, D., Ritz, L., Norquist, G., Howland, R. H., Lebowitz, B., McGrath, P. J., et al. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.1.28 · Cited by 3,879 · cited 1×
“Disease duration Median age at diagnosis (yrs) [range] 26 [13–72] 29 [12-62] 0.”
BackgroundThe molecular neurobiology of depression
Krishnan, V., & Nestler, E. J. (2008) · Nature · doi:10.1038/nature07455 · Cited by 2,889 · cited 1×
“Disease duration Median age at diagnosis (yrs) [range] 26 [13–72] 29 [12-62] 0.”
BackgroundFord, A. C., Talley, N. J., Schoenfeld, P. S., Quigley, E. M. M., & Moayyedi, P. (2009) · Gut · doi:10.1136/gut.2008.163162 · Cited by 582
Mittermaier, C., Dejaco, C., Waldhoer, T., Oefferlbauer-Ernst, A., Miehsler, W., Beier, M., Tillinger, W., Gangl, A., & Moser, G. (2004) · Psychosomatic Medicine · doi:10.1097/01.psy.0000106907.24881.f2 · Cited by 532
Stress and Exacerbation in Ulcerative Colitis: A Prospective Study of Patients Enrolled in Remission
Levenstein, S., Prantera, C., Varvo, V., Scribano, M. L., Andreoli, A., Luzi, C., Arcà, M., Berto, E., Milite, G., & Marcheggiano, A. (2000) · American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2000.02012.x · Cited by 451 · cited 1×
“Disease duration Median age at diagnosis (yrs) [range] 26 [13–72] 29 [12-62] 0.”
BackgroundWalker, J. R., Ediger, J. P., Graff, L. A., Greenfeld, J. M., Clara, I., Lix, L., Rawsthorne, P., Miller, N., Rogala, L., McPhail, C. M., et al. (2008) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2008.01980.x · Cited by 437
Predicting relapse in Crohn’s disease: a biopsychosocial model
Bitton, A., Dobkin, P. L., Edwardes, M. D., Sewitch, M. J., Meddings, J. B., Rawal, S., Cohen, A., Vermeire, S., Dufresne, L., Franchimont, D., et al. (2008) · Gut · doi:10.1136/gut.2007.134817 · Cited by 254
PERSOONS, P., VERMEIRE, S., DEMYTTENAERE, K., FISCHLER, B., VANDENBERGHE, J., VAN OUDENHOVE, L., PIERIK, M., HLAVATY, T., VAN ASSCHE, G., NOMAN, M., et al. (2005) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2005.02535.x · Cited by 253 · cited 1×
“Disease duration Median age at diagnosis (yrs) [range] 26 [13–72] 29 [12-62] 0.”
BackgroundPsychosocial determinants of relapse in ulcerative colitis: A longitudinal study
Bitton, A., Sewitch, M. J., Peppercorn, M. A., de B Edwardes, M. D., Shah, S., Ransil, B., & Locke, S. E. (2003) · American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2003.07717.x · Cited by 226
Cited by
Epidemiology and risk factors for IBD
Ananthakrishnan, A. N. (2015) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2015.34 · Cited by 1,741
Inflammatory bowel disease: Pathogenesis
Zhang, Y.-Z. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i1.91 · Cited by 1,507
Brain–Gut Interactions in Inflammatory Bowel Disease
Bonaz, B. L., & Bernstein, C. N. (2013) · Gastroenterology · doi:10.1053/j.gastro.2012.10.003 · Cited by 667
Depression and anxiety in inflammatory bowel disease: epidemiology, mechanisms and treatment
Bisgaard, T. H., Allin, K. H., Keefer, L., Ananthakrishnan, A. N., & Jess, T. (2022) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-022-00634-6 · Cited by 572
Bi-directionality of brain–gut interactions in patients with inflammatory bowel disease
Gracie, D. J., Guthrie, E. A., Hamlin, P. J., & Ford, A. C. (2018) · Gastroenterology · doi:10.1053/j.gastro.2018.01.027 · Cited by 408
The role of serotonin and its receptors in activation of immune responses and inflammation
Shajib, M. S., & Khan, W. I. (2015) · Acta Physiologica · doi:10.1111/apha.12430 · Cited by 369
Gracie, D. J., Hamlin, P. J., & Ford, A. C. (2019) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(19)30089-5 · Cited by 354
Microbiota-gut-brain axis and cognitive function
Gareau, M. G. (2014) · Advances in Experimental Medicine and Biology · doi:10.1007/978-1-4939-0897-4_16 · Cited by 189
Etiology and Treatment of Pain and Psychosocial Issues in Patients With Inflammatory Bowel Diseases
Regueiro, M., Greer, J. B., & Szigethy, E. (2017) · Gastroenterology · doi:10.1053/j.gastro.2016.10.036 · Cited by 142
Psychiatric co‐morbidity is associated with increased risk of surgery in Crohn's disease
Ananthakrishnan, A. N., Gainer, V. S., Perez, R. G., Cai, T., Cheng, S. ‐., Savova, G., Chen, P., Szolovits, P., Xia, Z., De Jager, P. L., et al. (2013) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.12195 · Cited by 122
Psychotherapy for inflammatory bowel disease: a review and update
McCombie, A. M., Mulder, R. T., & Gearry, R. B. (2013) · Journal of Crohn s and Colitis · doi:10.1016/j.crohns.2013.02.004 · Cited by 105
Tricyclic Antidepressants for Management of Residual Symptoms in Inflammatory Bowel Disease
Iskandar, H. N., Cassell, B., Kanuri, N., Gyawali, C. P., Gutierrez, A., Dassopoulos, T., Ciorba, M. A., & Sayuk, G. S. (2014) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0000000000000049 · Cited by 96
“24 Median TCA dose (range in mg) at first follow-up 25 (10-150) 25 (10-200) 0.”
Antidepressants in inflammatory bowel disease
Mikocka-Walus, A., Ford, A. C., & Drossman, D. A. (2020) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-019-0259-y · Cited by 93
Antidepressants in Inflammatory Bowel Disease: A Systematic Review
Macer, B. J. D., Prady, S. L., & Mikocka-Walus, A. (2017) · Inflammatory Bowel Diseases · doi:10.1097/mib.0000000000001059 · Cited by 92
Szigethy, E., Bujoreanu, S. I., Youk, A. O., Weisz, J., Benhayon, D., Fairclough, D., Ducharme, P., Gonzalez-Heydrich, J., Keljo, D., Srinath, A., et al. (2014) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1016/j.jaac.2014.04.014 · Cited by 86
(2017) · Europe PMC (PubMed Central) · Cited by 86
Yanartas, Ö., Kani, H. T., Bicakci, E., Kilic, I., Banzragch, M., Acikel, C., Atug, O., Kuscu, K., Imeryuz, N., & Akin, H. (2016) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s106039 · Cited by 69
“Usage of antidepressants to treat concomitant depression in patients with IBD was found to be associated with a decrease in relapse rates, steroid use, and number of endoscopies.(10) Most of the current literature studies address the need to determine the effects of antidepressant drug treatment on the IBD patient gro…”
BackgroundAlexakis, C., Kumar, S., Saxena, S., & Pollok, R. (2017) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.14171 · Cited by 69
“A small retrospective study has suggested a possible therapeutic benefit of ADMs in IBD reporting that patients treated with ADMs had fewer steroid courses in follow-up.(54) Conversely, a systematic review including 12 nonrandomised studies that assessed the efficacy of ADMs in IBD was inconclusive.”
BackgroundBhandari, S., Larson, M. E., Kumar, N., & Stein, D. (2017) · Gut and Liver · doi:10.5009/gnl16347 · Cited by 66
Adjuvant therapy with antidepressants for the management of inflammatory bowel disease
Mikocka-Walus, A., Prady, S. L., Pollok, J., Esterman, A. J., Gordon, A. L., Knowles, S., & Andrews, J. M. (2019) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012680.pub2 · Cited by 59
Tarricone, I., Regazzi, M. G., Bonucci, G., Rizzello, F., Carini, G., Muratori, R., Poggioli, G., & Campieri, M. (2017) · Journal of Psychosomatic Research · doi:10.1016/j.jpsychores.2017.07.001 · Cited by 53
Pediatric inflammatory bowel disease and depression: treatment implications
Keethy, D., Mrakotsky, C., & Szigethy, E. (2014) · Current Opinion in Pediatrics · doi:10.1097/mop.0000000000000129 · Cited by 40
“based on clinical opinion, reviews, and case reports in adults [64,65].”
BackgroundWang, J., Nakamura, T. I., Tuskey, A. G., & Behm, B. W. (2019) · Intestinal Research · doi:10.5217/ir.2019.00050 · Cited by 31
“Previous research has shown that antidepressants, when prescribed to treat concomitant mood disorders in IBD, may be associated with lower rates of clinical relapse and steroid use.(35) In addition, non-pharmacologic therapies including psychological counseling have been shown to improve the clinical course of IBD,(36…”
ResultSelective serotonin reuptake inhibitors and inflammatory bowel disease; Beneficial or malpractice
Hatamnejad, M. R., Baradaran Ghavami, S., Shirvani, M., Asghari Ahmadabad, M., Shahrokh, S., Farmani, M., Sherkat, G., Asadzadeh Aghdaei, H., & Zali, M. R. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.980189 · Cited by 28
“On the other hand, relieving IBD symptoms boosts the patients’ tolerance (16, 71), eliminating psychiatric comorbidities and reducing relapse rates (11, 72).”
BackgroundLuo, H., Sun, Y., Li, Y., Lv, H., Sheng, L., Wang, L., & Qian, J. (2018) · Journal of Psychosomatic Research · doi:10.1016/j.jpsychores.2018.07.013 · Cited by 25
The relationship of major depressive disorder with Crohn's disease activity
Facanali, C. B. G., Sobrado Junior, C. W., Fraguas Junior, R., Facanali Junior, M. R., Boarini, L. R., Sobrado, L. F., & Cecconello, I. (2023) · Clinics · doi:10.1016/j.clinsp.2023.100188 · Cited by 10
“29,34 According to some authors, women, elderly patients, and smokers are more likely to develop depression, 35,36 however, other authors disagree on the in fl uence of these clinical variables as a risk factor for depression in individuals with IBD.”
Background
Metadata
- Authors
- Goodhand, J. R., Greig, F. I. S., Koodun, Y., McDermott, A., Wahed, M., Langmead, L., & Rampton, D. S.
- Venue
- Inflammatory Bowel Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2012-07
- Volume
- 18
- Issue
- 7
- Pages
- 1232-1239
- ISSN
- 1078-0998 (ISSN-L)
- OpenAlex
- W2066850998
- Cited by
- 127
- References
- 18
- FWCI
- 6.39
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.